

SUMMARY OF PRODUCT CHARACTERISTICS (SPC)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SELGIAN 20 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient:	mg per tablet
Selegiline hydrochloride	20.00

Other ingredients:	
Titanium dioxide (E171)	3.6

For a full list of excipients see section 6.1

3. PHARMACEUTICAL FORM

Film-coated tablet.

Cross-scored film-coated tablets, divisible into quarters by means of a groove to facilitate accurate dosage.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs.

4.2 Indications for use

1. Treatment of behavioural disorders of purely emotional origin: depression, anxiety.
2. In association with behaviour therapy, treatment of signs of emotional origin observed in behavioural conditions such as over activity, separation problems, generalised phobia and unsociable behaviour.

Emotional disorders are characterised by a modification of feeding, drinking, auto-stimulatory behaviour, sleep, exploratory behaviour, aggression related to fear and/or irritation, social behaviour and somatic disorders (tachycardia, emotional micturition)

4.3 Contra-indications

1. Owing to its IMAO properties, (–) selegiline hydrochloride may act on prolactin secretion. In the absence of specific studies, it is recommended that the product should not be administered to pregnant and lactating bitches.

2. Do not administer the product from the day before until the day after anaesthesia or tranquillisation performed with an alpha-2 agonist.
3. Do not administer the product concomitantly with pethidine, fluoxetine or phenothiazines.
4. The narcotic action of morphine is potentiated by the product.

4.4 Special warnings for each target species

If no clinical improvement is observed after 2 months, continuing the treatment is not likely to provide any additional benefit.

It is advisable to weigh animals before dosing to ensure the correct mg/kg dosage is administered.

4.5 Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals

i) Special precautions for use in animals

Emotional disorders can mask hierarchical conflicts. In dominant dogs suffering from an emotional disorder, the alleviation of the disorder can sometimes reveal a latent aggressiveness. In such cases, behavioural therapy must be instituted.

ii) Special precautions to be taken by the person administering the medicinal product to animals:

In the event of accidental ingestion, seek medical advice and show the doctor the package leaflet.

Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

Trials have shown that some dominant dogs, with behavioural disorders but no signs of aggression, may become aggressive after treatment. Those previously showing aggression may have this enhanced. Appropriate training is essential in such cases.

4.7 Use during pregnancy, lactation or lay

It is recommend to stop the treatment during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

1. Do not administer the product from the day before until the day after an anaesthesia or tranquillisation performed with an alpha-2 agonist.
2. Do not administer the product concomitantly with pethidine, fluoxetine or phenothiazines.
3. The narcotic action of morphine is potentiated by the product.

4.9 Amounts to be administered and administration route

Route of administration: Oral use.

According to the dosage the tablet can be divided into 4.

0.42 mg/kg/day of selegiline, corresponding to 0.5 mg/kg/day selegiline hydrochloride (1 film-coated tablet 20 mg per 40 kg BW) in a single administration in the morning to fasting dogs.

Dog weight in kg	Number of tablets
≥ 26 < 36	$\frac{3}{4}$
≥ 36 < 46	1
≥ 46 < 56	$1\frac{1}{4}$
≥ 56 < 66	$1\frac{1}{2}$
≥ 66 < 76	$1\frac{3}{4}$
≥ 76 < 86	2

The treatment should be continued until the clinical condition is stable.

The minimum treatment period recommended is 2 months, based on the clinical trials results:

The treatment period was 2 to 3 months for 20 % of the dogs

The treatment period was 4 to 5 months for 50 % of the dogs

The treatment period was 6 to 7 months for 20 % of the dogs

The treatment period was > 7 months for 10 % of the dogs

The treatment can be stopped suddenly without gradual dose reductions.

4.10 Overdose (Symptoms, emergency procedures, antidotes)

Unlikely to occur.

4.11 Withdrawal periods

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Therapeutic Group: Nervous system, ATC Vet Code QN06AX90

5.1 Pharmacodynamic properties

(-) selegiline hydrochloride is an inhibitor of monoamine oxidase (IMAO-B) at the therapeutic dose in the dog; thus it modifies the concentration of monoaminergic neurotransmitters.

5.2 Pharmacokinetic properties:

(–) selegiline hydrochloride is quickly absorbed after oral administration. The oral bioavailability ranges from 65 to 95 % in the dog.

Selegiline binds rapidly and durably onto the specific cerebral receptors. The duration of the pharmacological effect following such binding is independent of the maintenance of blood levels.

Selegiline is quickly metabolised into l-desmethyloselegiline, l-amphetamine and l-metamphetamine. At the therapeutic dose recommended in the dog, these derivatives have no pharmacological activity.

Repeated administration of Selgian showed the absence of any cumulative effect after 91 days in the beagle dog.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Titanium dioxide
Povidone K30
Maize starch
Lactose monohydrate
Microcrystalline cellulose
Magnesium stearate
Hydrochloric acid
Hypromellose
Cellulose microcrystalline
Macrogol stearate 40
Purified water

6.2 Major incompatibilities

Do not administer with other alpha-2 agonists.

6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 5 years
Shelf life after opening immediate packaging: 4 days

6.4 Special precautions for storage

Do not store above 25°C.

The tablets are divisible into quarters. Tablet portions can be kept for 4 days in the blister packs.

6.5 Nature and contents of container

Nature of primary container

Polyvinylchloride film / Aluminium foil blister pack

Models intended for sale

Box containing 3 blisters of 10 tablets

Box containing 5 blisters of 10 tablets

Box containing 10 blisters of 10 tablets

Box containing 50 blisters of 10 tablets

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused medicinal product or waste materials if any

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

CEVA SANTE ANIMALE
Z.I de la Ballastière BP 126
33501 Libourne CEDEX
France

8. MARKETING AUTHORISATION NUMBER

Vm 14966/4004

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

26th October 2006

10. DATE OF REVISION OF THE TEXT

25th September 2007